Hemoglobin, hematologic support, and bleeding-directed systemic therapies. The patient required multiple pRBC transfusions on almost a monthly basis to maintain her hemoglobin despite multiple attempted therapies. She was trialed on aspirin therapy at month −12 but continued to have refractory GI bleeding. After starting treatment with bevacizumab 5 mg/kg at time 0, she became transfusion independent and successfully tolerated aspirin, which allowed for her TAVR. TID, 3 times per day.